82 related articles for article (PubMed ID: 19523861)
1. Mammalian target of rapamycin: a new target in prostate cancer.
Rai JS; Henley MJ; Ratan HL
Urol Oncol; 2010; 28(2):134-8. PubMed ID: 19523861
[TBL] [Abstract][Full Text] [Related]
2. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
Kobayashi T; Shimizu Y; Terada N; Yamasaki T; Nakamura E; Toda Y; Nishiyama H; Kamoto T; Ogawa O; Inoue T
Prostate; 2010 Jun; 70(8):866-74. PubMed ID: 20127734
[TBL] [Abstract][Full Text] [Related]
3. Activation of the mammalian target of rapamycin signalling pathway in prostate cancer and its association with patient clinicopathological characteristics.
Dai B; Kong YY; Ye DW; Ma CG; Zhou X; Yao XD
BJU Int; 2009 Oct; 104(7):1009-16. PubMed ID: 19389013
[TBL] [Abstract][Full Text] [Related]
4. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in cyclin D proteins.
Xu Y; Chen SY; Ross KN; Balk SP
Cancer Res; 2006 Aug; 66(15):7783-92. PubMed ID: 16885382
[TBL] [Abstract][Full Text] [Related]
5. Activation of mTOR signaling pathway contributes to survival of cervical cancer cells.
Ji J; Zheng PS
Gynecol Oncol; 2010 Apr; 117(1):103-8. PubMed ID: 20102778
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia.
Martelli AM; Evangelisti C; Chiarini F; Grimaldi C; Manzoli L; McCubrey JA
Expert Opin Investig Drugs; 2009 Sep; 18(9):1333-49. PubMed ID: 19678801
[TBL] [Abstract][Full Text] [Related]
7. Functional consequences of mTOR inhibition.
Sudarsanam S; Johnson DE
Curr Opin Drug Discov Devel; 2010 Jan; 13(1):31-40. PubMed ID: 20047144
[TBL] [Abstract][Full Text] [Related]
8. The rationale for mTOR inhibition in epithelial ovarian cancer.
Trinh XB; van Dam PA; Dirix LY; Vermeulen PB; Tjalma WA
Expert Opin Investig Drugs; 2009 Dec; 18(12):1885-91. PubMed ID: 19888868
[TBL] [Abstract][Full Text] [Related]
9. [Can defective TGF-Beta signaling be an Achilles heel in human cancer?].
Foster DA; Gadir N
Ai Zheng; 2008 Aug; 27(8):882-4. PubMed ID: 18710627
[TBL] [Abstract][Full Text] [Related]
10. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
[TBL] [Abstract][Full Text] [Related]
11. Glucocorticoids increase NPY gene expression in the arcuate nucleus by inhibiting mTOR signaling in rat hypothalamic organotypic cultures.
Shimizu H; Arima H; Ozawa Y; Watanabe M; Banno R; Sugimura Y; Ozaki N; Nagasaki H; Oiso Y
Peptides; 2010 Jan; 31(1):145-9. PubMed ID: 19818818
[TBL] [Abstract][Full Text] [Related]
12. Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma.
Subbiah IM; Brown RE; Fallon MB
Hepatology; 2010 Oct; 52(4):1524. PubMed ID: 20680964
[No Abstract] [Full Text] [Related]
13. Iron deficiency down-regulates the Akt/TSC1-TSC2/mammalian Target of Rapamycin signaling pathway in rats and in COS-1 cells.
Ndong M; Kazami M; Suzuki T; Uehara M; Katsumata S; Inoue H; Kobayashi K; Tadokoro T; Suzuki K; Yamamoto Y
Nutr Res; 2009 Sep; 29(9):640-7. PubMed ID: 19854379
[TBL] [Abstract][Full Text] [Related]
14. Post-transcriptional regulation of the androgen receptor by Mammalian target of rapamycin.
Cinar B; De Benedetti A; Freeman MR
Cancer Res; 2005 Apr; 65(7):2547-53. PubMed ID: 15805247
[TBL] [Abstract][Full Text] [Related]
15. Novel targeted therapies for prostate cancer.
Macfarlane RJ; Chi KN
Urol Clin North Am; 2010 Feb; 37(1):105-19, Table of Contents. PubMed ID: 20152524
[TBL] [Abstract][Full Text] [Related]
16. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
17. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
[TBL] [Abstract][Full Text] [Related]
18. [mTOR inhibitors: temsirolimus and everolimus in the treatment of renal cell carcinoma].
Ravaud A; Bernhard JC; Gross-Goupil M; Digue L; Ferriere JM
Bull Cancer; 2010; 97():45-51. PubMed ID: 20418203
[TBL] [Abstract][Full Text] [Related]
19. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
20. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
